Jinling Pharmaceutical Co., Ltd. (000919)
XSHE XSHE Primary SSE Summary
000919 Chart
Jinling Pharmaceutical Co., Ltd. Dividends
| 0009 000919 31 May 2024 | Other | ¥0.1 Per Share |
| 0009 000919 14 Jul 2023 | Other | ¥0.1 Per Share |
| 0009 000919 11 Aug 2022 | Other | ¥0.1 Per Share |
| 0009 000919 12 Aug 2021 | Other | ¥0.1 Per Share |
| 0009 000919 13 Aug 2020 | Other | ¥0.17 Per Share |
Jinling Pharmaceutical Co., Ltd. Earnings
| 21 May 2025 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | 0.03 EPS |
| 27 Aug 2024 Date | | - Cons. EPS | 0.01 EPS |
| 21 May 2024 Date | | - Cons. EPS | 0.08 EPS |
| 31 Oct 2023 Date | | - Cons. EPS | 0.04 EPS |
| 0009 000919 31 May 2024 | Other | ¥0.1 Per Share |
| 0009 000919 14 Jul 2023 | Other | ¥0.1 Per Share |
| 0009 000919 11 Aug 2022 | Other | ¥0.1 Per Share |
| 0009 000919 12 Aug 2021 | Other | ¥0.1 Per Share |
| 0009 000919 13 Aug 2020 | Other | ¥0.17 Per Share |
| 21 May 2025 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | 0.03 EPS |
| 27 Aug 2024 Date | | - Cons. EPS | 0.01 EPS |
| 21 May 2024 Date | | - Cons. EPS | 0.08 EPS |
| 31 Oct 2023 Date | | - Cons. EPS | 0.04 EPS |
Jinling Pharmaceutical Co., Ltd. (000919) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Jinling Pharmaceutical Co., Ltd. ever had a stock split?
Jinling Pharmaceutical Co., Ltd. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Hai Chen CEO | XSHE Exchange | CNE0000010W5 ISIN |
| CN Country | 5,789 Employees | - Last Dividend | 10 Jul 2006 Last Split | 27 Aug 1999 IPO Date |
Overview
Jinling Pharmaceutical Company Limited is a distinguished entity in China's pharmaceutical sector, focusing on the manufacturing and distribution of a broad array of pharmaceutical products and medical devices. Founded in 1998 and rooted in Nanjing, China, the company has committed itself to addressing a range of health conditions through its extensive product offerings. It stands out for its dedication to innovation and quality in providing solutions for various medical needs, along with offering medical and health care services that further underscore its role in enhancing patient care and treatment outcomes.
Products and Services
Mailuoning Injection/Oral Solutions
Designed to treat an array of vascular diseases such as thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and its sequelae, polyarteritis, acute arterial embolism of the extremities, diabetic gangrene, intravenous thrombus, and thrombophlebitis, Mailuoning injection/oral solutions represent a pivotal part of Jinling Pharmaceutical’s product line.
Ferrous Succinate Tablets
These tablets are formulated to prevent and treat iron deficiency anemia, catering to patients who suffer from this condition by providing an essential mineral supplementation that contributes to the overall blood health and functionality.
Lentinan Injection
Aimed at the treatment of malignant tumors, lentinan injections embody Jinling Pharmaceutical's foray into oncology, offering a therapeutic solution that supports the standard cancer treatment protocols and potentially improves patient outcomes.
Absorbable Gelatin Sponges
This medical device is designed for wound hemostasis, suitable for various medical situations where rapid blood coagulation and healing are paramount. The sponges absorb bodily fluids and provide a scaffold for blood clotting, aiding in the wound healing process.
Contact Information
